The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19223511.
- Also identified by DOI 10.1158/1078-0432.CCR-08-0640 and PMC identifier 2780737.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Breast cancer 1 (BRCA1) was initially identified as one of the genes conferring genetic predisposition to both breast and ovarian cancer. One of the interesting aspects of BRCA1-linked cancers is the observed specificity for estrogen-responsive tissues such as breast and ovary. Recent advances in our understanding of BRCA1-linked breast cancers have revealed a complex relationship between BRCA1 and estrogen receptor alpha (ERalpha) signaling. Estrogen stimulation increases expression of BRCA1 at the mRNA and protein level and conversely BRCA1 functions to both induce ERalpha mRNA expression and act as a negative regulator of ERalpha signaling. Here, we review the relationship between BRCA1 and ERalpha and discuss the use of antiestrogen therapies such as tamoxifen and aromatase inhibitors in the treatment of BRCA1 mutation carriers.
Medical subject headings
- BRCA1 Protein
- Breast Neoplasms
- Estrogen Receptor alpha
- Genetic Predisposition to Disease